Empty Capsules Market: Increased demand for vegetarian empty capsules in developing markets to create significant revenue traction

Steady increase in the number of photochemically unstable drugs will continue to positively influence the growth of the empty capsules market in 2016, with global revenues expected to increase by 6% to reach US$ 1,432.6 Mn. 

Increasing demand for vegan and Halal pharmaceuticals is ramping up adoption, and providing support to a market, which is primarily driven by Type-A (pork-based) capsules. Development of hypromellose capsules for the treatment of pulmonary and non-pulmonary diseases are also creating growth opportunities for manufacturers.

Gelatin-based capsules will continue to account for higher demand than vegetarian-based capsules, accounting for nearly 71% revenue share of the market in 2016.  Type-A (pork skin), the largest segment in terms of raw materials, will grow at a lower rate than non-pork based empty capsules, especially hydroxy propyl methyl cellulose (HPMC) and fish bone gelatin. While type-A (pork skin) revenues will grow by 4.62% in 2016, fish bone gelatin and HPMC revenues will grow by 8.87% and 8.40% respectively.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-782  

Size “4” capsules will continue to be the largest revenue segment on the basis of capsule size, with total revenues expected to reach US$ 263.1 Mn in 2016. Size “1” and Size “2” capsules will also account for substantial demand, collectively accounting for over US$ 430 Mn in market revenues in 2016.

Empty capsules are administered orally, and only a small percentage of these drugs is inhaled – the former accounted for 91.1% revenue share of the global market in 2015. While inhalation-based empty capsules will grow at a higher rate, they will continue to account for a revenue share of less than 10% of the overall market.

Pharmaceutical companies – the largest end-use segment for empty capsules – will continue to post strong gains in 2016. Revenues from this segment are anticipated to increase at 5.79% in 2016 to total US$ 940.8 Mn. Demand will also be healthy in the cosmetics and nutraceutical sector, with this segment collectively accounting for nearly US$ 360 Mn in revenues in 2016.

The U.S. is the largest market for empty capsules, with total revenues expected to reach US$ 500 Mn in 2016. The North America empty capsules market (U.S. and Canada) is the largest globally in terms of revenues, accounting for nearly 43% revenue share of the market. Western Europe will maintain its position as the second largest market for empty capsules, with total revenues expected to reach US$ 279.4 Mn in 2016. Germany and France are the two largest markets in terms of revenues, with the former accounting for the highest revenue share and the latter growing at the highest rate.

Key players in the global empty capsules market included include Capsugel, ACG Worldwide, CapsCanada Corporation, Roxlor LLC, Qualicaps, Inc., Suheung Co., Ltd., Medi-Caps Ltd., Sunil Healthcare Ltd., Snail Pharma Industry Co., Ltd. and Bright Pharma Caps, Inc.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-782

Long-term Outlook: The global empty capsules market is anticipated to increase at a CAGR of over 7% to reach US$ 2,902.5 Mn in revenues by 2026.

Digital Pathology Market: Increasing Adoption in Cancer Research and Diagnosis to boost the market for Digital Pathology Scanning

Future Market Insights (FMI) recently announced the release of its report titled “Digital Pathology Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2025.” According to the report, the global digital pathology market, estimated to be valued at US$ 326.7 Mn in 2015-end, is expected to expand at over 11% CAGR to total US$ 954.4 Mn by 2025.

According to FMI’s report, growing need for real-time access to pathology outcomes is a key factor fuelling widespread adoption of digital pathology services. Increasing initiatives by pharmaceutical companies to develop novel medicines for cancer treatment has also contributed to increase the scope of digital pathology systems.

Adoption of digital pathology services and solutions is anticipated to witness robust growth in the regions of North America and Western Europe, owing to favourable regulations and affordability. Although the use of digital pathology in primary diagnosis is restricted in the U.S., robust adoption across research centres has provided an impetus to the market in the country.

A sample of this report is available upon request @  https://www.futuremarketinsights.com/reports/sample/rep-gb-124

According to FMI’s report, Asian countries are facing challenges in adopting digital pathology solutions owing to high cost structure, complexity in practical implementation of cloud-based digital pathology systems, and a general lack of awareness about digital pathology systems.

FMI’s report has segmented the digital pathology market on the basis of components, screening services, and end-users. The report also offers region-wise forecast and analysis on the key companies operating in the digital pathology landscape.

On the basis of components, the digital pathology market is broadly segmented into hardware, software and services.

The hardware segment includes scanner and other platform technologies, which currently accounts for major share of the global market. The software segment comprises on-premises software and cloud-based software. The on-premises software solution sub-segment has been estimated to account for largest share in the overall digital pathology software market in 2015.

On the basis of screening services, the histopathology screening segment has been estimated to account for 81% share of the overall digital pathology market in 2015. This is attributed to increasing usage of digital pathology systems in cancer research for histopathology screening of test samples.

On the basis on end user, the research centre segment is estimated to remain dominant in the global digital pathology market over the forecast period, owing to higher adoption among drug discovery and development industry, which includes, research centres, contract research organisation and others. This segment has been estimated to account for 63% share of the overall digital pathology market revenue in 2015.

Key trends identified in the digital pathology market include use of digital pathology as second-opinion collaboration technology in cancer treatment, increasing research activities in personalized medicines, and integration of LIS, LIMS and EMR solution with digital pathology.

Implementation of image lifecycle management, disaster recovery solutions, tiered storage management plans in data management in on-premises as well as cloud-based solution are driving the adoption of digital pathology in the healthcare sector globally.

Leading Companies in Digital Pathology Market

Key market players covered in the report include Perkin Elmer, Inc., MedImmune, LLC (AstraZeneca), Sectra AB, Koninklijke Philips N.V, GE Healthcare, Inspirata Co., Ventana Medical Systems, Inc., Leica Biosystems, 3D-Histech Ltd, Hamamatsu Photonics, K.K., Digipath Co., ZEISS, Olympus Corporation, and Yokogawa Electronic Corporation.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-124

These leading players are bolstering their position through product launches and acquisitions as a key development strategy in order to sustain their position in the competitive market. The Tier 1 companies are focusing on a collaborative approach with cloud service providers to provide overall service to end-users.

Contrast Media Injectors Market to expand at a CAGR of 5.6% by 2025

Future Market Insights (FMI), in its latest report titled ‘Contrast Media Injectors Market: Global Industry Assessment and Forecast, 2015-2025’, has projected the global contrast media injectors market revenue to expand at a CAGR of 5.6% during the forecast period (2015-2025).

The global contrast media injectors market was valued at US$ 979.5 Mn and accounted for 3.0% share of the global diagnostics imaging devices market in 2014. Revenue contribution of contrast media injectors market to the global diagnostics imaging devices market is expected to increase to US$ 1,773.4 Mn by the end of 2025, expanding at a CAGR of 5.6% in terms of value during the forecast period. Continuous adoption of contrast media injectors for contrast media insertion owing to benefits on offer such as increased patient safety, reduced contrast media wastage and increasing demand for early diagnosis of chronic diseases are expected to positively affect growth of the contrast media injectors market across the globe. Global contrast media injectors market has been estimated to be valued at US$ 1,029.2 Mn in 2015, mainly driven by increasing adoption of contrast media injectors in the field of oncology and cardiology.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-823 

The report analyses the global contrast media injectors market in terms of market value (US$ Mn) and market volume (units) by product, region and end user, and provides information regarding market dynamics, competitive landscape, current trends, market estimation and forecast.

Adoption rate of contrast media injectors amongst physicians has increased significantly, owing to technological advancements and benefits such as superior prognosis of medical condition due to enhanced quality of images obtained post contrast media insertion. Emergence of alternative techniques for diagnosis of disease such as cancer and side effects caused due to contrast media are certain factors that are expected to hamper growth of the global contrast media injectors market to a certain extent. Major trends in the contrast media injectors market include increased adoption of syringeless contrast media injectors for reduction of contrast media wastage, introduction of advanced software to make the device more user friendly and consistent investment in research and development.

North America dominated the contrast media injectors market with over 33.5% share in terms of value in 2014, and is expected to remain dominant throughout the forecast period. The contrast media injectors market in APEJ and Japan are expected to register robust CAGRs of 5.7% and 5.8% respectively, in terms of value, during the forecast period. Western Europe and Eastern Europe are expected to lose revenue share over the forecast period, as contrast media injectors market is relatively mature in these regions due to increasing adoption of alternative techniques for diagnosis of chronic diseases.

On the basis of product type, contrast media injectors market is segmented into CT injectors, MRI injectors and cardiology injectors. In terms of volume growth, CT injectors segment is expected to account for the maximum share in the market. MRI injectors segment is expected to register highest CAGR over the forecast period, in terms of volume. CT injectors segment is expected to dominate the global contrast media injectors market, in terms of revenue, owing to increasing adoption of combination systems. In terms of volume and value, cardiology injectors segment is expected to register lowest CAGR over the forecast period.

On the basis of end user, contrast media injectors market is segmented into hospitals, ambulatory surgical centres and diagnostics centres. In terms of value and volume, diagnostics centres segment is expected to register lowest CAGR during the forecast period. Hospitals segment revenue growth is majorly driven by increasing installations of imaging modalities in hospitals. Increasing adoption of contrast media injectors among physicians for early diagnosis of chronic disease, especially in the field of oncology and cardiology is fueling revenue growth of the contrast media injectors market.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-823

Some of the key market participants included in the report are Mallinckrodt, Guerbet SA, Bayer AG, Bracco Imaging S.p.A., Ulrich GmbH & Co. KG., Medtron AG and Nemoto Kyorindo Co. Ltd.

Increasing out-of-pocket healthcare expenditure and patent expiries of blockbuster drugs fuelling the global branded generics market

A recent research conducted by Future Market Insights predicts that the global market for branded generics will witness a steady growth in terms of revenues. Over a ten-year forecast period from 2016 to 2026, the size of global branded generics market has been estimated to expand at a steady CAGR of 7.3%. Brand-name prescriptions will continue to be ubiquitous among aged people in the world, and since geriatric demographics account for a large portion of global drug-consuming population, demand for branded generics will also rise substantially. In 2016, the global branded generics market has been valued at nearly US$ 200 billion, and is projected to reach US$ 413.8 Bn market valueby the end of forecast period.

A sample of this report is available upon request @  https://www.futuremarketinsights.com/reports/sample/rep-gb-1260

Some of the leading manufacturers of branded generics are based in Asian countries, and are extending their production capacity to keep up with the surging global depend. In Asia-Pacific excluding Japan (APEJ) region, about US$ 150 billion revenues are expected to be procured by the end of 2026. During the forecast period, branded generics market in the APEJ region will attain fastest growth, registering a 10% CAGR, contributing over 35% of global branded generics revenues. North America, Eastern Europe and Latin America are also expected to be lucrative for growth of branded generics sales, while revenues in Western Europe, Japan and Middle East & Africa (MEA) are likely to incur a considerable dip by 2026-end.

Competitive Timeline in Global Branded Generics Market

• Since 2015, Abbott Laboratories, a leading drugmaker in the global pharmaceuticals industry, has aimed at capitalizing from branded generics businesses in developing regions.
• Teva Pharmaceuticals acquired Allergan’s branded generics vertical, while Pfizer Inc. bought Hospira Inc. – both acquisitions have been strategically carried out for repositioning market standings of Teva and Pfizer respectively.
• In December 2016, India-based Sun Pharmaceuticals Industries Ltd. agreed to buy Swiss drugmaker Novartis AG’s branded generics portfolio on cancer medications.
• Another leading branded generics manufacturer, Mylan N.V. recently launched anti-allergy devices which are expected to be half the price of its branded EpiPens.
• Other prominent companies partaking in the growth of global branded generics market include, Aspen Pharmacare Holding Ltd. and Valeant Pharmaceuticals International, Inc.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-1260

Research Highlights on Global Branded Generics Market

The report includes a segmental analysis of the global branded generics market, fragmenting its growth on the type of drug formulation, major drug classes, therapeutic applications, and distribution channels. Based on such segmentation, some of the key findings compiled in the report are:

• Nearly three-fifth of the global branded generics revenues estimated in 2016 are expected to be accounted by oral-type formulations, with parenteral, topic and other formulation types collectively accounting for 8% market value share.
• Hospital pharmacies & retail pharmacies will remain as the largest distribution channels for branded generics throughout the globe.
• In 2016 and beyond, the demand for branded generics in therapeutic treatment of cardiovascular diseases will be significant, revenues from which are expected to increase at more than 8% CAGR over the forecast period.
• Global revenues of branded generics accounted by anti-hypertensive drug class are predicted to surpass US$ 25 billion by 2026-end.

Bone Growth Stimulators Market will reach at a CAGR of 9.5% from 2015 to 2025

According to the latest market report published by Future Market Insights titled, “Bone Growth Stimulators Market: Global Industry Analysis and Opportunity Assessment, 2015-2025”, the bone growth stimulators market is anticipated to expand at a CAGR of 9.5% during the forecast period.

Bone growth stimulators are used in cases of delay or failure of fracture healing as they enhance the bone healing process without the sensation of electrical shocks or currents or vibrations when worn by the user. An internal bone growth stimulator or invasive bone growth stimulator is implanted on the fusion site of the bone and it delivers small electrical currents. The internal bone growth stimulator is removed from the body after 6-12 months. External bone growth stimulator or non-invasive bone growth stimulators are externally worn portable devices and do not require surgical implantation. An external bone growth stimulator is prescribed for use for two to nine hours every day for a period of around three to nine months.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-828

Economic factors such as improvement in service sector, increase in personal income, and increase in per capita healthcare expenditure are expected to drive market growth globally. Captivating product features, expanding application in the sports medicine industry, high disability cost payments, among others, are fuelling growth of the global bone growth stimulators market. However, various factors such as availability of alternative therapies, uncertainty about efficacy, device-related issues and competition from bone grafts restraint growth of the bone growth stimulators market.

By product, the global bone growth stimulators market is segmented into invasive bone growth stimulators, non-invasive bone growth stimulators and ultrasound bone growth stimulators. The non-invasive bone growth stimulators product segment-which comprises capacitive coupling devices, combined magnetic field devices and pulsed ultrasound magnetic field devices-accounts for the highest market share currently and is expected to remain the leading segment in terms of value during the forecast period. In terms of application segmentation, trauma injury and fractures segment is expected to expand at the highest CAGR in terms of value and volume over the forecast period as compared to other applications. Hospitals end user segment, though projected to account for the highest share in market, is expected to expand at an average CAGR in terms of value and volume over the forecast period. Orthopedic clinics and home care end user segments are expected to represent significant market attractiveness indices over the forecast period.

By region, North America is expected to remain the market leader in the bone growth stimulators market mainly due to consumer awareness about chronic pain related to bone fracture and injury and subsequent disability costs. Western Europe is the second-largest contributor to the global market in terms of value and volume owing to availability of public health systems and subsidies coupled with reliance of patients on the Internet to research about new technologies, such as bone growth stimulators. MEA is projected to expand at a significant pace mainly due to large (particularly expatriate) population, improvements in life expectancy and decline in mortality rates, combined with increased budgetary spend on healthcare, resulting in a major shift and boost in growth of the bone growth stimulators market in the MEA countries. The MEA bone growth stimulators market is still untapped, so companies have substantial growth opportunities in this region.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-828

Key market players covered in this report are DJO LLC, Orthofix International N.V., Zimmer Biomet Holdings Inc., Elizur, Bioventus LLC., Ossatec Benelux BV, Verve Consulting Inc. and IGEA S.p.A. Major players in the bone growth stimulators market are focusing on enhancing their global and regional presence through strategic mergers & acquisitions and operational expansion.

Urinary Tract Infection Treatment Market to Grow at a CAGR of 2.1% through 2026

Over 60% physicians are likely to prescribe penicillin and combinations to treat urinary tract infections (UTIs), whereas a vast majority prescribe quinolones in their daily practice to treat complicated cases. A significant percentage of physicians also agreed that they prescribed nitrofurans to treat uncomplicated urinary tract infections in female patients. FMI’s survey also found that cephalosporin is the second-most common drug in the treatment of recurrent and complicated urinary tract infections. 

Prevalence of urinary tract infections is higher in females as compared to males, with biologic and behavioural factors accounting for the major causes. Development of this ailment due to genetic causes or urogenital surgery and Estrogen deficiency was minimal.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1340  

FMI’s survey also found that prevalence of uncomplicated URI was significantly higher than complicated-, recurring complicated UTIs. However, prevalence of complicated UTI is expected to increase in the future, owing to increase in drug-resistant bacteria and excessive use of antibiotics.

The global urinary tract infection treatment market is expected to reach US$ 9.42 Bn in revenues. Complex regulatory requirements and low investment in research and development are some of the key factors for sluggish growth of the market. Clinical trials for designing antibacterial drugs are quite complex, owing to which a number of major companies have decreased their R&D spending on the development of new drugs. Moreover, UTI are not chronic like blood pressure or heart diseases and patients are symptom-free usually within 1-2 weeks of treatment, resulting into limited sales of the drugs. In addition to these factors, economic and regulatory hurdles are also restraining the growth of the urinary tract infection treatment market.

By drug type, quinolones account for the highest revenue share of the global urinary tract infection treatment market. This segment is expected to account for nearly 37.2% share of the global urinary tract infection treatment market revenues in 2016. This represents a market value of nearly US$ 3.5 Bn, up from US$ 3.43 Bn in 2015. Among quinolones, levofloxacin is the most sought-after drug type, representing nearly US$ 1.59 Bn in revenues in 2015. Penicillin and combinations is the second largest drug type, and is expected to total US$ 1.87 Bn in revenues.

Retail pharmacies will continue to remain the largest segment in terms of distribution channel in 2016. This segment accounts for nearly 56.8% revenue share, representing a market value of US$ 5.35 Bn. Gynaecology and urology clinics collectively is the second largest segment by distribution channel.

By disease indication, uncomplicated UTI will continue to dominate global revenues. This segment currently accounts for a revenue share of 52.7%, representing a market value of US$ 4.96 Bn in 2016. Neurogenic bladder infections, the second-largest segment by disease indication, is expected to increase by 2.30% in 2016.

Asia Pacific excluding Japan (APEJ) will continue to be the leading market for urinary tract infections, with total revenues expected to reach US$ 3.46 Bn in 2016. Western Europe and North America will remain the second and third largest markets respectively.

Key players operating in the urinary tract infection treatment market include Johnson & Johnson, Boehringer Ingelheim, Cipla Ltd., Bayer AG, GSK, Roche Ltd., Pfizer Inc., Novartis AG, and AstraZeneca plc. The key strategy of a majority of these key players is to expand in emerging markets and achieving inorganic growth through mergers and acquisitions.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-1340

Long-term Outlook: The global urinary tract infection treatment market is anticipated to increase at a CAGR of 2.1% during the forecast period 2016-2026 and reach US$ 11.58 Bn in revenues.

Ophthalmic Diagnostic Equipment Market Estimated to Exhibit 5.4% CAGR through 2025

According to the latest market report published by Future Market Insights, titled “Ophthalmic Diagnostic Equipment Market: Global Industry Analysis and Opportunity Assessment 2015-2025”, the ophthalmic diagnostic equipment market is expected to be valued at US$ 2,168.0 Mn by the end of 2015. It is anticipated to expand at a CAGR of 5.4% during the forecast period (2015-2025) to account for US$ 3,656.0 Mn by 2025.

Ophthalmic devices are medical devices used to identify ocular defects or deficiencies and treat eye disorders. As a result of the constant developments in ophthalmic technology for effective treatment of eye diseases and restoration of vision, more and more number of people are opting for ophthalmic surgeries to rectify their eye-related disorders. As per the World Health Organization (WHO) 2010 estimates, there were 285 Mn visually impaired people across the globe in 2010, which included 39 Mn blind people, of whom around 80% were above the age of 50 years. Ophthalmology is the branch of medical science that deals with anatomy, physiology, and disease of the eye. There are various diagnostic equipment that are used to diagnose a wide range of ophthalmic conditions and provide vision solution. These equipment are simple to use for healthcare professionals.

A sample of this report is available upon request @  https://www.futuremarketinsights.com/reports/sample/rep-gb-771

Increasing prevalence of eye-related disorders such as macular degeneration and diabetic retinopathy, rise in aging population and increasing government initiatives towards the development of healthcare infrastructure in the developing countries are the key factors driving growth of the global ophthalmic devices market currently. 

In addition, increasing prevalence of lifestyle associated diseases, such as diabetes and high blood pressure, is fuelling growth of the market further. In case of the geriatric population, treatment of eye diseases calls for more effective ophthalmology devices. Several government associations across the globe are also focused on increasing consumer awareness about ophthalmic diseases. However, various factors, such as lack of awareness about eye diseases and high risks associated with eye surgeries, act as restraints for growth of the ophthalmology devices market. Also, there are some problems associated with the use of ophthalmology devices; for instance, changes made to the cornea cannot be reversed after LASIK surgery.

By region, North America dominated the ophthalmic diagnostic equipment market with over 31.1% value share in 2014 and is expected to remain dominant throughout the forecast period. The ophthalmic diagnostic equipment market in Asia and Latin America is expected to expand at a CAGR of 5.9% and 5.7%, respectively, in terms of value, during the forecast period. Meanwhile, the Optical Coherence Tomography (OCT) product segment is expected to account for the maximum value share of the overall market during the forecast period.

Dearth of ophthalmologists and lack of associations capable of understanding the needs of the ophthalmologists are among the major factors restraining growth of the ophthalmic diagnostic equipment market currently. Meanwhile, factors such as launch of advanced technologies, product innovation, new patent approvals and research institutes and universities play a major role in driving the market growth.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-771

Key market players covered in this report are TOPCON CORPORATION, Carl Zeiss Vision International GmbH, Ellex, Quantel Medical Inc, NIDEK CO., LTD, HAAG-STREIT GROUP, Halma plc, Coburn Technologies Inc. and Kowa Company Ltd. Major players in the ophthalmic diagnostic equipment market focus on enhancing their global and regional presence through strategic acquisitions and mergers, and operational expansion.

Neonatal Thermoregulation Market will Register a CAGR of 5.0% through 2027

Future Market Insights presents a new report titled ‘Neonatal Thermoregulation Market: Global Industry Analysis 2012 – 2016 and Opportunity Assessment 2017 – 2027’ that studies the performance of the global neonatal thermoregulation market over a 10 year assessment period from 2017 to 2027. The report presents the value forecasts of the global neonatal thermoregulation market and provides pertinent insights into the various factors driving market growth as well as the factors restricting market growth. As per the assessment of Future Market Insights, the global neonatal thermoregulation market was estimated to be valued at nearly US$ 500 Mn in 2017 and is expected to reach a valuation of about US$ 800 Mn by 2027, and in the process exhibit a CAGR of 5.0% during the period of forecast 2017-2027.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5881  

International Companies Targeting Emerging Economies for Lucrative Opportunities in the Neonatal Thermoregulation Market

The companies involved in the manufacturing and marketing of neonatal care equipment are shifting their focus towards emerging economies such as China, India, South Africa, Brazil and Mexico. Multinational companies are especially targeting the Asian markets for developing neonatal infant care equipment due to a significant demand and a potentially large customer base. For instance, in 2013, Koninklijke Philips N.V. entered the mother and childcare business segment, where it manufactures infant warms and incubators at affordable prices as compared to other market players in India. In December 2013, the GE Healthcare designed models to improve quality of neonatal care. The company launched two products for neonatal care in India, the new Lullaby Warmer Prime, and Lullaby Resus. The cost was about 40% lower than the existing offerings from GE, so that the products are easily accessible in low-middle income economic countries. Companies in the Asia Pacific region are developing innovative solutions to meet the growing needs of the neonatal care and treatment market. Companies, such as MTTS Asia and Pluss Advanced Technologies Pvt. Ltd. have developed innovative products, such as Miracradle and MTTS Firefly, catering to the demand for cooling systems in the region.

Global Neonatal Thermoregulation Market: Segmentation and Forecast

The global neonatal thermoregulation market is segmented on the basis of product type, modality, end user and geography.

• By product type, the neonatal incubators segment was estimated to be valued at nearly US$ 250 Mn in 2017 and is likely to reach a valuation of nearly US$ 410 Mn in 2027, exhibiting a CAGR of 5.2% during the period of assessment 2017-2027.
• By modality, the closed segment was estimated to be valued at nearly US$ 270 Mn in 2017 and is anticipated to witness a CAGR of 4.7% during the period of forecast.
• By end user, the hospitals segment is expected to reach a valuation of nearly US$ 430 Mn in 2027.
• By geography, the Asia Pacific neonatal thermoregulation market was estimated to be valued at nearly US$ 170 Mn in 2017 and is likely to reach a valuation of about US$ 295 Mn in 2027, exhibiting a CAGR of 5.5% during the period of forecast.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-5881

Global Neonatal Thermoregulation Market: Competitive Landscape

In this report, some of the important companies functioning in the global neonatal thermoregulation market have been profiled in the competitive landscape section. Some of the prominent companies that have been featured include GE Healthcare, Natus Medical Incorporated., Inspiration Healthcare Group plc, Koninklijke Philips N.V., Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare, International Biomedical, Ltd., Atom Medical Corporation, Fanem Ltda, Novos Medical Systems, Pluss Advanced Technologies Pvt. Ltd., Weyer GmbH, BabyBloom Healthcare BV and Medical Technology Transfer and Services Asia.

Amino Acid Metabolism Disorders Treatment Market to expand at a steady CAGR of 6.4% by 2026

 The global amino acid metabolism disorders treatment market is expected to exhibit a strong growth over the course of the forecast period. The report on global amino acid metabolism disorders treatment market has been minutely studied and researched upon by the analysts of Future Market Insights (FMI). The market research report presents an all-inclusive analysis of the global amino acid metabolism disorders treatment market along with an outline of the competition existing among the core players operating in the market. The vendor landscape section includes several facets pertaining to key players such as innovation and developments, product portfolio,  core strategies, geographical area covered, prime personnel, mergers, acquisitions, agreements, and other financial and non-financial strategies.

According to Future Market Insights, the global amino acid metabolism disorders treatment market is expected to rise at a CAGR of 6.4% from 2017 to 2026. The market is projected to touch a valuation of over US$1,030 Mn by the end of the forecast period.

A sample of this report is available upon request @  https://www.futuremarketinsights.com/reports/sample/rep-gb-6359

Key Insights on Amino Acid Metabolism Disorders Treatment Market

On the basis of region, the global amino acid metabolism disorders treatment market has been segmented into North America, Europe, Latin America, Asia Pacific except Japan, Japan, and the Middle East and Africa. Amongst these, North America is expected to retain a leading position in the market by the end of the forecast period reaching a valuation of over US$359 Mn. North America is expected to be closely followed by Europe. Players operating in this market can seek potential opportunities from the U.S., Germany, Spain, and France owing to several clinical trials taking place pertaining to this treatment and several mergers and acquisitions occurring among core players operating in these regions. Players can also find lucrative opportunities from Asia Pacific excluding Japan and as well with the rise in nutritional management activities in these regions. Countries in APAC such as China and India are also expected to emerge as potential adopters of amino acid metabolism disorders treatment in the long run.

In terms of product type, the global amino acid metabolism disorder treatment market has been segmented into arginine, folic acid, vitamin B6 and B12, thiamine, vitamin D, betaine, carglumic acid, sapropterin dihydrocholoride, and others. Among these, carglumic acid is expected to lead the market until the end of the forecast period reaching a valuation of over US$185 Mn. However, sapropterin dihydrocholoride is expected to witness the maximum growth rate over the course of the forecast period.

Based on indication, the global market for amino acid metabolism disorder treatment has been classified into phenylketonuria, maple syrup urine disease, argininosuccinic acidemia, citrullinemia, and homocystinuria. Among all of these, phenylketonuria is expected to emerge dominant by the end of the forecast period.

On the basis of sales channel, the global market for amino acid metabolism disorder treatment has been classified into hospital pharmacies, retail pharmacies, and online sales. Hospital pharmacies is expected to take the lead among all these by the end of the forecast period.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/askus/rep-gb-6359

Vendor Landscape

The companies operating in the market are Pfizer, Inc., GlaxoSmithKline PLC, Merck KGaA, Koninklijke DSM N.V., Recordati S.p.A., Sanofi, Civentichem, LLC, Shine Star (Hubei) Biological Engineering Co., Ltd., AMINO GmbH, and Kyowa Hakko Kirin Co., Ltd.